

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

---

**BEFORE THE PATENT TRIAL AND APPEAL BOARD**

---

FAMY CARE LIMITED

Petitioner

v.

ALLERGAN, INC.

Patent Owner

U.S. Patent No. 8,642,556 B2 to Acheampong *et al.*

Issue Date: February 4, 2014

Title: Methods of Providing Therapeutic Effects Using Cyclosporin Components

---

*Inter Partes* Review Trial No. 2017-00700

---

**PETITIONER'S MOTION FOR JOINDER  
PURSUANT TO 35 U.S.C. § 315(c) AND 37 C.F.R. §§ 42.22 AND 42.122(b)**

**TABLE OF CONTENTS**

I. STATEMENT OF THE PRECISE RELIEF REQUESTED ..... 1

II. STATEMENT OF MATERIAL FACTS ..... 2

III. STATEMENT OF REASONS FOR RELIEF REQUESTED ..... 5

    A. Reasons Why Joinder Is Appropriate..... 6

        1. Identical Grounds and Similar Petitions ..... 7

        2. Consolidated Discovery ..... 8

    B. No New Grounds of Unpatentability ..... 10

    C. No Impact on IPR Trial Schedule ..... 11

    D. Joinder Will, on Balance, Simplify Discovery..... 11

    E. Joinder Will Not Prejudice Patent Owner or Mylan ..... 12

IV. PROPOSED ORDER ..... 13

V. CONCLUSION..... 14

## TABLE OF AUTHORITIES

### Cases

<i>Amneal Pharma., Inc. v. Yeda Res. and Dev. Co., Ltd.</i> , IPR2015-01976 .....	2
<i>Apotex Inc. and Mylan Pharmaceuticals Inc., v. Novartis AG and Mitsubishi Pharma Corp</i> , IPR2015-00518.....	10
<i>Dell, Inc. v. Network-1 Security Solutions, Inc.</i> , IPR2013-00385.....	6
<i>Kyocera Corp. et al. v. Softview LLC</i> , IPR2013-0004 .....	1
<i>Microsoft Corp. v. Proxyconn, Inc.</i> , IPR2013-00109.....	7
<i>Motorola Mobility LLC v. Softview LLC</i> , IPR2013-00256 .....	2
<i>Mylan Pharmaceuticals, Inc. v. Allergan, Inc.</i> , IPR2016-01129 .....	1, 14
<i>Torrent Pharmaceuticals Ltd. v. Novartis AG and Mitsubishi Pharma Corp</i> , IPR2014-00784 .....	11

### Statutes

35 U.S.C. § 315(b) .....	12
35 U.S.C. § 315(c) .....	1, 5
35 U.S.C. § 316(b) .....	6

### Other Authorities

37 C.F.R. § 42.1(b) .....	6
37 C.F.R. § 42.122(b).....	1, 2, 5
37 C.F.R. § 42.22 .....	1, 2, 5

### Treatises

157 CONG. REC. S1376 (daily ed. Mar. 8, 2011).....8

## I. STATEMENT OF THE PRECISE RELIEF REQUESTED

Petitioner Famy Care Limited (“Famy Care” or “Petitioner”) filed the present petition for *inter partes* review (“the Famy Care IPR”) and respectfully submits this Motion for Joinder. Pursuant to 35 U.S.C. § 315(c), 37 C.F.R. §§ 42.22, and 42.122(b), Famy Care requests institution of an *inter partes* review concerning U.S. Patent No. 8,642,556 B2, which issued on February 4, 2014, to Acheampong *et al.* (“the ‘556 patent”) and joinder with the *inter partes* review concerning the same patent in *Mylan Pharmaceuticals, Inc. v. Allergan, Inc.*, assigned Case No. IPR2016-01129, (the “Mylan IPR”), which was instituted on December 8, 2016.

In accordance with the Board’s Representative Order identifying matters to be addressed in a motion for joinder (*Kyocera Corp. et al. v. Softview LLC*, Paper No. 15, IPR2013-0004, Apr. 24, 2013), Petitioner submits that: (1) joinder is appropriate because it will promote efficient determination of the validity of the ‘556 patent without prejudice to the prior petitioners, Mylan Pharmaceuticals, Inc. (“Mylan”), or to the owners of the ‘556 patent, Allergan, Inc. (“Allergan” or “Patent Owner”); (2) Famy Care’s Petition raises virtually the same grounds of unpatentability over the same prior art references as those instituted by the Board in the Mylan IPR; (3) joinder would not affect the pending schedule in the Mylan IPR nor unduly increase the complexity of that proceeding, thereby minimizing costs; and (4) Petitioner is willing to agree to consolidated discovery of Patent Owner witnesses with Mylan to minimize

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.